The Opportunity.
Switzerland spends roughly CHF 1.5 billion a year on prevention, yet screening still requires a clinic visit — no operator delivers it at the workplace today.
TAM → SAM → SOM · capital-efficient scaling
Execution-First Position
No operator delivers employer-site preventive screening in Switzerland at this price point today — but mobile fleets exist and B2B screening players are entering. Our lead is execution speed, not exclusivity.
≈40% Cost Advantage
Remote supervision by Swiss-licensed physicians over an on-site nurse/sonographer crew cuts physician cost by roughly 40% versus an on-site physician model.
Regulatory Moat
MEBEKO-recognized Swiss-licensed physicians + cantonal operating licenses + QUALAB accreditation (in preparation) create a multi-layer regulatory barrier that takes 12–18 months to replicate.
Capital-Efficient Scaling
Each phase-2 van pays back within 10 months. Expansion is modular: add units, add cities, add revenue. No facility buildout required.
Four Revenue Streams.
Diversified revenue base across direct employer contracts, mandatory insurance, complementary coverage, and clinical trial recruitment.
Employer B2B
Direct contracts with Swiss employers for on-site preventive screening programmes. Per-employee, per-visit pricing.
Reimbursement Model
Basic insurance (LAMal) does not cover preventive screening (KVG Art. 32). Revenue is private pay (employer) plus employee upsell; supplementary (VVG) plans often contribute. A formal legal opinion on billing is in preparation.
VVG Insurance
Complementary insurance partnerships for expanded screening panels. Premium wellness positioning for insurer members.
Trial Recruitment
Clinical trial patient identification and pre-screening for pharma partners. High-margin, data-leveraged revenue.
Detailed Materials Available Under NDA
Our financial model, unit economics, funding structure, regulatory timeline, and exit analysis are available to qualified investors upon signing a non-disclosure agreement.
Financial Model
10-sheet Excel with P&L, cash flow, sensitivity, unit economics
NDA RequiredFunding Structure
Round details, dilution table, cap table, milestone gates
NDA RequiredUnit Economics
Per-patient waterfall, per-unit economics (phase 2), break-even analysis
NDA RequiredRegulatory Pathway
MEBEKO timeline, cantonal licensing, Swiss-licensed physician network
On RequestExit Analysis
Potential acquirers, valuation scenarios, comparable transactions
NDA RequiredFull Whitepaper
30-section clinical, regulatory, and operational business plan
On RequestHow It Works
Request Access
Fill in the form below with your details and investment interest.
Sign NDA
We send you a mutual NDA. Once signed, you receive the full investor package.
Review & Meet
Review the materials, schedule a call with the founding team.
Request Full Prospectus
Access the complete investor materials including financial model, pitch deck, and whitepaper.
Request Received
We will send the prospectus materials to your email within 24 hours.
Includes:
Prevention should meet people where they work.
Switzerland spends roughly CHF 1.5 billion a year on prevention — yet chronic diseases still account for 80% of healthcare costs. The gap isn't in spending. It's in access.
Ventve brings clinically validated preventive diagnostics directly to Swiss workplaces. A transportable kit (mobile units from phase 2), telemedicine oversight, and results within 24 hours — no clinics, no waiting rooms, no friction.
We exist to make early detection the easiest thing an employee does all year.
Send Us a Message
Questions, partnership ideas, or just want to talk? Reach out directly.
Message Sent
Thanks for reaching out. We'll get back to you within 48 hours.
Prefer email? investors@ventve.com